What is the role of serological markers in the diagnosis of IBD?
Research and technological advancements have fostered a novel approach to understanding the intricate relationship between genetic and clinical expression of disease. Both genetic and serum antibody markers hold the most promise in helping researchers better comprehend disease heterogeneity and natural history. Although our current gold standard diagnostic tests do not possess this capability, exciting preliminary research suggests IBD-specific antibody markers may serve as predictors of an individual's disease course. Thus, the foundation has been laid upon which the discovery of novel IBD-specific and IBD-sensitive markers will enable researchers to identify at-risk individuals, as well as diagnose IBD and stratify patients into homogeneous subtypes with certainty. Clinicians can then create and implement individual treatment plans designed to improve the long-term prognosis of these chronic diseases.
Dubinsky
Marla C
MC
UCLA School of Medicine, Pediatric IBD Center, Cedars Sinai Medical Center, California, USA.
D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005819:Genetic Markers; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood* / Q000175:diagnosis; D011379:Prognosis; D012680:Sensitivity and Specificity; D012698:Serologic Tests
D019268:Antibodies, Antineutrophil Cytoplasmic; D015415:Biomarkers; D005819:Genetic Markers